Angel investors might invest in one of every 100 opportunities that come before them—long odds for a startup, for sure. Ann Arbor-based RetroSense Therapeutics, a privately-held biopharmaceutical company, had already beat those odds, having raised $7 million in a 2014 angel-led Series A financing round that included Midland’s Blue Water Angels Investment Network. But the […]